VERTEX PHARMACEUTICALS INC / MA Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $502.97 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-02-13
- VERTEX PHARMACEUTICALS INC / MA share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $502.97, a 25.83% increase from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $399.71, a 16.63% increase from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $342.73, a 24.10% increase from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $276.17, a 27.15% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2025-12-31 | $502.97 10-K · filed 2026-02-13 |
| 2024-12-31 | $399.71 10-K · filed 2025-02-13 |
| 2023-12-31 | $342.73 10-K · filed 2024-02-15 |
| 2022-12-31 | $276.17 10-K · filed 2023-02-10 |
| 2021-12-31 | $217.20 10-K · filed 2022-02-09 |
| 2020-12-31 | $286.27 10-K · filed 2021-02-11 |
| 2019-12-31 | $184.50 10-K · filed 2020-02-13 |
| 2018-12-31 | $164.11 10-K · filed 2019-02-13 |
| 2017-12-31 | $108.43 10-K · filed 2018-02-15 |
| 2016-12-31 | $91.36 10-K · filed 2017-02-23 |
| 2015-12-31 | $119.09 10-K · filed 2016-02-16 |
| 2014-12-31 | $84.33 10-K · filed 2015-02-13 |
| 2013-12-31 | $57.87 10-K · filed 2014-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |